Luminescence Technology Corp. (6729.TWO)
New Taipei City, TW
Luminescence Technology Corp., established in 2001 with its headquarters in New Taipei City, Taiwan, operates as a prominent global manufacturer and distributor of advanced organic chemicals. The company's market reach extends across North America, Europe, Asia, and its home base of Taiwan. Its comprehensive product portfolio serves various high-tech industries, featuring a wide range of organic light-emitting diode (OLED) materials, including thermally activated delayed fluorescent (TADF) compounds, small molecular, and polymer solution-processed OLEDs. They also supply essential materials for organic photovoltaics (OPV), such as small molecular/oligomeric and polymeric compounds, hole/electron transport materials, self-assembled monolayers, and components for perovskite and dye-sensitized solar cells. Furthermore, their offerings include materials for organic photodiodes (OPD) and perovskite-based photodiodes (PPD). The company is also a key provider of materials for organic thin-film transistors (OTFT) and organic field-effect transistors (OFET). They deliver complete material solutions for flexible printed electronics, encompassing OPV and OTFT/OFET applications, alongside crucial layers like hole transport, injection, host, light-emitting, and electron transport/hole blocking polymers. Luminescence Technology Corp.'s expertise extends to photonic and optical device materials, which include porphyrins, phthalocyanines, and specialized dyes, in addition to quantum dot materials. A substantial portion of their business focuses on a vast array of synthetic intermediates and reagents, covering diverse chemical classes such as arylamines, naphthalenes, anthracenes, fluorenes, pyrenes, triphenylenes, chrysenes, carbazole derivatives, various heterocyclics, iridium complexes and ligands, silane derivatives, thiophene derivatives, benzene derivatives, boronic acids and esters, and a selection of metal catalysts and reductants. Their specialized chemical offerings further encompass polyimide, aggregation-induced emission (AIE) materials, organic electrode materials, metal-organic frameworks (MOFs)/covalent organic frameworks (COFs), photoresist materials, and bioscience materials. The bioscience segment specifically includes pharmaceutical intermediates, inhibitors, traditional Chinese medicine reference reagents, nucleosides, nucleotides, nucleic acids, and additional metal catalysts/reductants. Beyond chemical compounds, the company also supplies crucial components like substrate and encapsulation materials, evaporation parts, and finished OLED panels and drivers. Additionally, they provide specialized equipment for rapid drying processes, coating, UV light processing, and measurement tools for both OLED and OPV technologies.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.17% | +13.55% | -5.56% | -10.93% | +53.15% | +51.40% | +142.86% | +231.48% | +230.56% | +135.18% | +135.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals: +4.0%+14.5% ★ Q4'25: +1.9% (vs Q4'23)
-
EPS growth Chemicals: +11.7%+8.7% Q4'25: -43.0% (vs Q4'23)
-
FCF margin FCF growth · Chemicals: +41.7%+20.7% Q4'25: +57.4% (vs Q4'23)
-
EBIT margin Chemicals: +7.1%+14.3% ★ Q4'25: +7.4% (vs Q4'23)
-
ROIC Chemicals: +3.4%+10.0% ★ Q4'25: +8.9% (vs Q4'23)
-
Share dilution Chemicals: +0.0%+2.2% Q4'25: +3.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×0.15× ★ Q4'25: 0.12× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fengwen Yan | GM & Chairman | — | male |
| Qingyan Zhao | Deputy General Manager of Operation Management Department | — | male |
| Yanjin Guo | Director of Finance, Accounting & Corporate Governance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6729.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
